Jakob Ito
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jakob Ito has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Ahmed Idbaih
Sorbonne Université, Inserm, CNRS, UMR S 1127, Paris Brain Institute (ICM), Equipe labellisée Ligue Nationale contre le Cancer Paris France
31 shared publications - Alba Ariela Brandes
Nervous System Medical Oncology Department, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy
31 shared publications - Andreas von Deimling
Department of Neuropathology, Heidelberg University Hospital, University of Heidelberg, Heidelberg, Germany
31 shared publications - Antje Wick
Department of Neurology and Neurooncology Program, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany
31 shared publications - Daniel Schrimpf
Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg University , Heidelberg
31 shared publications - Felix Sahm
Department of Neuropathology, University Hospital Heidelberg, Heidelberg, Germany
31 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
Supplementary Figure 5: Copy number variants in the three main glioblastoma groups according to classifier v12.5. A Copy number variants in all patients combined (n = 295), B in RTK1 tumors (n = 89), C in RTK2 tumors (n = 140) and D in MES tumors (n = 66). PDGFRA amplifications are enriched in RTK1 tumors and gains of chromosomes 19 and 20 are enriched in RTK2 tumors.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
Supplementary Figure 5: Copy number variants in the three main glioblastoma groups according to classifier v12.5. A Copy number variants in all patients combined (n = 295), B in RTK1 tumors (n = 89), C in RTK2 tumors (n = 140) and D in MES tumors (n = 66). PDGFRA amplifications are enriched in RTK1 tumors and gains of chromosomes 19 and 20 are enriched in RTK2 tumors.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
Supplementary Table 1: Representativeness of study participants.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
Supplementary Table 1: Representativeness of study participants.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
Supplementary Figure 1: Overview of the clinical trial and biomarker analysis. Out of 596 patients in the EORTC-26101 trial, patient tumor tissue to perform DNA methylation (Meth) and NGS sequencing analysis was available from 380 patients (63.8%). Of these, 99 patients treated with lomustine and 189 patients treated with lomustine and bevacizumab were eligible to detect biomarkers for bevacizumab response.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
Supplementary Figure 1: Overview of the clinical trial and biomarker analysis. Out of 596 patients in the EORTC-26101 trial, patient tumor tissue to perform DNA methylation (Meth) and NGS sequencing analysis was available from 380 patients (63.8%). Of these, 99 patients treated with lomustine and 189 patients treated with lomustine and bevacizumab were eligible to detect biomarkers for bevacizumab response.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
Supplementary Figure 3: Characteristics of RTK1 tumors in comparison to RTK2 and MES. A Distribution of MGMT promotor methylation in main glioblastoma methylation subgroups. Classifier assignment is based on the v12.5 version (n = 295). Mutational profiles in B RTK1 tumors (n = 89), C RTK2 tumors (n = 140) and D MES tumors (n = 66).
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
Supplementary Figure 3: Characteristics of RTK1 tumors in comparison to RTK2 and MES. A Distribution of MGMT promotor methylation in main glioblastoma methylation subgroups. Classifier assignment is based on the v12.5 version (n = 295). Mutational profiles in B RTK1 tumors (n = 89), C RTK2 tumors (n = 140) and D MES tumors (n = 66).
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
Supplementary Figure 7: Exceptional survivors of the EORTC-26101 study (n = 78).
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
Supplementary Figure 7: Exceptional survivors of the EORTC-26101 study (n = 78).
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
Supplementary Figure 2: Overall (A) and progression-free (B) survival in the EORTC-26101 clinical study (n = 596) and EORTC-26101 biomarker cohort (n = 380).
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
Supplementary Figure 2: Overall (A) and progression-free (B) survival in the EORTC-26101 clinical study (n = 596) and EORTC-26101 biomarker cohort (n = 380).
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
Supplementary Figure 4: Multivariate analysis. Baselines were MGMT = “methylated” and Classifier = “GBM MES”. Classifier assignment is based on the v12.5 version (n = 380).
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
Supplementary Figure 4: Multivariate analysis. Baselines were MGMT = “methylated” and Classifier = “GBM MES”. Classifier assignment is based on the v12.5 version (n = 380).
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
Supplementary Figure 6: Overall Survival according to PTEN mutation status in the group of IDH-wildtype glioblastomas (n = 362).
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
Supplementary Figure 6: Overall Survival according to PTEN mutation status in the group of IDH-wildtype glioblastomas (n = 362).
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
Supplementary Table 2: Characteristics of patients with RTK1 tumors compared to RTK2 and MES according to classifier version v12.5. P-value was calculated for comparison between RTK1 and both other groups (RTK2 and MES) combined. NA, not available.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
Supplementary Table 2: Characteristics of patients with RTK1 tumors compared to RTK2 and MES according to classifier version v12.5. P-value was calculated for comparison between RTK1 and both other groups (RTK2 and MES) combined. NA, not available.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Prognostic markers of DNA methylation and NGS sequencing in progressive glioblastoma from the EORTC-26101 trial
Supplementary Figure 6: Overall Survival according to PTEN mutation status in the group of IDH-wildtype glioblastomas (n = 362).
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Prognostic markers of DNA methylation and NGS sequencing in progressive glioblastoma from the EORTC-26101 trial
Supplementary Figure 6: Overall Survival according to PTEN mutation status in the group of IDH-wildtype glioblastomas (n = 362).